Bushman E C, Nayak R N, Bushman W
Department of Urology, Brown University, Providence, Rhode Island.
J Urol. 1995 Jan;153(1):233-7. doi: 10.1097/00005392-199501000-00083.
A total of 124 specimens of prostate tissue (25 normal prostate, 41 benign prostatic hyperplasia, 58 adenocarcinoma) was immunostained for ras p21 using a commercially available monoclonal antibody directed against a peptide sequence conserved among all members of the ras gene family. Of normal prostate specimens, 76% showed no staining while the remainder showed only weak epithelial (glandular) staining. No significant stromal staining was noted in any normal prostate specimen. In contrast most benign prostatic hyperplasia specimens showed abundant staining. Epithelial staining was observed in 88% and stromal staining in 73% of specimens. A majority of prostate carcinoma specimens also stained, with 62% and 36% showing epithelial and stromal staining, respectively. No association was noted between staining and either tumor grade or clinical stage. These data argue against any clinical usefulness of immunostaining for ras p21 in the diagnosis or grading of prostate cancer.
使用针对ras基因家族所有成员中保守肽序列的市售单克隆抗体,对总共124份前列腺组织标本(25份正常前列腺组织、41份良性前列腺增生组织、58份腺癌组织)进行ras p21免疫染色。在正常前列腺标本中,76%无染色,其余仅显示弱上皮(腺)染色。在任何正常前列腺标本中均未观察到明显的间质染色。相比之下,大多数良性前列腺增生标本显示大量染色。88%的标本观察到上皮染色,73%的标本观察到间质染色。大多数前列腺癌标本也有染色,分别有62%和36%显示上皮和间质染色。染色与肿瘤分级或临床分期之间未发现关联。这些数据表明,ras p21免疫染色在前列腺癌的诊断或分级中无任何临床实用性。